Dr. Perez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Medical Center Dr
Lebanon, NH 03756Phone+1 603-650-8626Fax+1 603-650-7791
Education & Training
Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1985 - 1988
Northeast Ohio Medical UniversityClass of 1985
Certifications & Licensure
KS State Medical License 2011 - 2017
NH State Medical License 1998 - 2012
Clinical Trials
- A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors Start of enrollment: 2010 Mar 01
- A Study in Advanced Solid Tumors Start of enrollment: 2010 Jun 01
- Study in Advanced Solid Tumors Start of enrollment: 2010 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsThe effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours.Darcy B. Pooler, Dylan B. Ness, John Sarantopoulos, Nicholas Squittieri, Shoba Ravichandran
British Journal of Clinical Pharmacology. 2021-03-01 - 2 citationsCorrection to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.Lori J. Goldstein, Raymond P. Perez, Denise A. Yardley, Linda K. Han, James M. Reuben
Breast Cancer Research. 2020-05-20 - 60 citationsA Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple MyelomaIrene M. Ghobrial, Chia Jen Liu, Robert A. Redd, Raymond P. Perez, Rachid Baz
Clinical Cancer Research. 2020-01-15
Press Mentions
KU Cancer Center Makes Bid to Join Elite ClubSeptember 26th, 2016
Grant Support
- Protocol-Specific Research SupportNational Cancer Institute2009–2012
- Data And Safety MonitoringNational Cancer Institute2009–2012
- SPRY2 Predicts Survival Post-Chemotherapy In Advanced Ovarian Cancer.National Cancer Institute2010
- SPRY2 Predicts Survival Post-Chemotherapy In Advanced Ovarian Cancer.National Cancer Institute2009–2010
- Inhibition Of S14 By Conjugated Linoleic Acid In Advanced Solid Tumor PatientsNational Cancer Institute2009–2010
- Clinical ResearchNational Cancer Institute2004–2008
- Modulation Of Clinical Sensitivity To ChemotherapyNational Cancer Institute2000–2004
- Atorvastatin, A Prenylation Inhibitor In Acute Leukemia.National Cancer Institute2002–2003
Professional Memberships
- Member
- American Society of Pharmacology and Experimental Therapeutics - ASPETMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
